Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
J Immunol Res. 2022 Apr 4;2022:9621466. doi: 10.1155/2022/9621466. eCollection 2022.
Concurrent chemoradiotherapy (CCRT) has been widely applied to locally advanced cervical cancer (LACC) patients, inducing the massive release of antigen and systematic immunomodulatory effects. However, its effect on the soluble immune checkpoint proteins (sICPs) remains unclear, which might play a key role in the immune response. Therefore, the current study explored changes in the levels of 16 sICPs in LACC patients during CCRT.
We prospectively enrolled fifty-one LACC patients treated with CCRT and collected patients' blood before, during and after CCRT. The levels of 16 sICPs were measured using the Luminex platform, and the changes were measured using Friedman test with Bonferroni's posttest. One month after CCRT, the tumor response was evaluated according to the RECIST 1.1 guidelines.
The levels of soluble T-cell immunoglobulin and mucin-domain containing-3 (sTIM-3) significantly increased during CCRT ( = 0.041), while those of the soluble B and T lymphocyte attenuator (sBTLA), sCD40, soluble glucocorticoid-induced tumor necrosis factor receptor ligand (sGITRL), sCD80, sCD86, sPD-1, sPD-L1, sCTLA-4, and soluble inducible T-cell costimulator (sICOS) significantly increased after CCRT (all < 0.05). Other sICPs showed no significant changes throughout the CCRT (all > 0.05). 41 (80%), 8 (16%), and 2 (4%) patients showed complete response (CR), partial response (PR), and stable disease (SD) after CCRT, respectively. Interestingly, the level of soluble lymphocyte-activation gene 3 (sLAG-3) was significantly higher among the PR/SD patients as compared to the CR after CCRT ( = 0.009).
This study revealed that CCRT might elevate the serum levels of sTIM-3, sBTLA, sCD40, sGITRL, sCD80, sCD86, sPD-1, sPD-L1, sCTLA-4, and sICOS in the patients with LACC. The sLAG-3 level was higher in the patients with poor response to CCRT. These findings revealed the dynamic changes in the sICPs levels during CCRT, which might be helpful in designing optimal treatment strategies for LACC patients.
同步放化疗(CCRT)已广泛应用于局部晚期宫颈癌(LACC)患者,诱导大量抗原释放和系统免疫调节作用。然而,其对可溶性免疫检查点蛋白(sICPs)的影响尚不清楚,这可能在免疫反应中起关键作用。因此,本研究探讨了 LACC 患者在 CCRT 过程中 sICPs 水平的变化。
前瞻性纳入 51 例接受 CCRT 的 LACC 患者,并在 CCRT 前、中、后采集患者血液。采用 Luminex 平台检测 16 种 sICPs 的水平,采用 Friedman 检验和 Bonferroni 事后检验测量变化。CCRT 后 1 个月,根据 RECIST 1.1 指南评估肿瘤反应。
CCRT 过程中可溶性 T 细胞免疫球蛋白和粘蛋白结构域包含 3(sTIM-3)水平显著升高(=0.041),而可溶性 B 和 T 淋巴细胞衰减物(sBTLA)、可溶性糖皮质激素诱导的肿瘤坏死因子受体配体(sGITRL)、可溶性 CD40、可溶性 CD80、可溶性 CD86、可溶性 PD-1、可溶性 PD-L1、可溶性 CTLA-4 和可溶性诱导性 T 细胞共刺激分子(sICOS)水平在 CCRT 后显著升高(均<0.05)。其他 sICPs 在整个 CCRT 过程中均无显著变化(均>0.05)。CCRT 后,41(80%)、8(16%)和 2(4%)例患者分别完全缓解(CR)、部分缓解(PR)和疾病稳定(SD)。有趣的是,与 CCRT 后 CR 相比,PR/SD 患者可溶性淋巴细胞激活基因 3(sLAG-3)水平显著升高(=0.009)。
本研究表明,CCRT 可能会升高 LACC 患者血清中 sTIM-3、sBTLA、sCD40、sGITRL、sCD80、sCD86、sPD-1、sPD-L1、sCTLA-4 和 sICOS 的水平。CCRT 后 sLAG-3 水平在反应不佳的患者中更高。这些发现揭示了 CCRT 过程中 sICPs 水平的动态变化,这可能有助于为 LACC 患者设计最佳治疗策略。